Preventing Deep Venous Thrombosis in Hospitalized Patients

King, Mitchell S.
May 1994
American Family Physician;5/1/1994, Vol. 49 Issue 6, p1389
Academic Journal
Presents information on how to prevent pulmonary embolism by preventing the occurrence of deep venous thrombosis. Predisposing factors involved; Effectiveness of various prophylactic treatments; Risk of hemorrhagic complications in the perioperative period; Cost-effectiveness of prophylactic measures; Guidelines for prophylaxis; Risk being higher in surgical patients than in medical patients.


Related Articles

  • Secondary prophylaxis with oral anticoagulant therapy.  // American Family Physician;10/1/1995, Vol. 52 Issue 5, p1500 

    Reports on a study from the June 22, 1995 issue of the `New England Journal of Medicine,' by Schulman and colleagues comparing the effectiveness of six weeks of oral anticoagulant therapy with that of six months of therapy for secondary prophylaxis. Results indicating that six months of...

  • Peroneal nerve palsy following sequential pneumatic compression. Pittman, Gregory R.; Pittman, G R // JAMA: Journal of the American Medical Association;4/21/89, Vol. 261 Issue 15, p2201 

    Focuses on the use of a sequential pneumatic compression device (SPCD) for deep venous thrombosis and pulmonary embolism. Preoperative application of the SPCD to the lower extremities; Description of the device.

  • AMPLIFY trial results.  // Hospital Medicine Alert;Sep2013 Pharmacology Watch, p2 

    The article discusses research done on the effects of apixaban and anticoagulant therapy in patients with acute venous thromboembolism (VTE) published online in the July 1, 2013 issue of the "New England Journal of Medicine."

  • FDA actions.  // Primary Care Reports;Sep2011 Supplement, p2 

    The article reports on the approval given by the U.S. Food and Drug Administration to the oral factor Xa inhibitor rivaroxaban. The drug is designed for patients undergoing knee or hip replacement to reduce the risk of deep venous thrombosis, blood clots, and pulmonary embolism. The article...

  • AMPLIFY trial results.  // Critical Care Alert;Sep2013 Pharmacology Watch, p2 

    The article focuses on the AMPLIFY clinical trial conducted on patients with acute venous thromboembolism (VTE) to compare the effectiveness of conventional anticoagulant therapy with oral anticoagulant apixaban.

  • AMPLIFY trial results. Elliott, William T. // Clinical Cardiology Alert;Sep2013 Pharmacology Watch, p2 

    The article focuses on the results of the AMPLIFY trial which compares the efficacy of apixaban with conventional anticoagulant therapy in acute venous thromboembolism (VTE) patients.

  • Sequential Compression Devices and Clots. Ashworth, Suzanne C. // Critical Care Nurse;Dec2014, Vol. 34 Issue 6, p68 

    The article presents a question and an answer related to the use of sequential compression devices (SCDs) in patients with deep venous thrombosis.

  • Rivaroxaban: a novel anticoagulant. Haalstrup, Margaret; Williams, Helen // British Journal of Cardiac Nursing;Feb2013, Vol. 8 Issue 2, p68 

    Rivaroxaban is an oral anticoagulant licensed for the treatment of acute deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. It is also licensed for the prevention of stroke and systemic embolism in adult patients with...

  • Using heparin (dalteparin) in pregnancy is not effective in reducing complications of thrombophilia.  // Midwifery News;Dec2014, Issue 75, p35 

    The article discusses the lack of effectiveness over the use of dalteparin to reduce the occurrence of venous thromboembolism in pregnant women wherein it consider the use of routine thromboprophylaxis in all women except for those with the highest level of pregnancy risk. It states that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics